Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm
Published on 08/07/2025 at 18:05 | prnewswire.co.uk
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx's system seeks to enhance identification of people who may have BPDCN, leveraging actual images of BPDCN skin lesions and artificial intelligence/machine learning (AI/ML) technologies incorporated into the VisualDx platformView original content:https://www.prnewswire.co.uk/news-releases/menarini-group-announces-collaboration-with-visualdx-to-aid-in-identifying-people-who-may-have-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-302407123.html
en | boerse | 67967931 |
